Potent antibody therapeutics by design (Q36452621)

14 August 2017

1 reference

title

Potent antibody therapeutics by design (English)

1 reference

14 August 2017

1 reference

Paul J Carter

1

1 reference

14 August 2017

publication date

1 May 2006

1 reference

Nature Reviews Immunology

14 August 2017

published in

1 reference

14 August 2017

volume

6

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

343-357

1 reference

Ten years of Orthoclone OKT3 (muromonab-CD3): a review

14 August 2017

cites work

1 reference

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

21 January 2018

1 reference

Engineered antibodies with increased activity to recruit complement

21 January 2018

1 reference

Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn.

21 January 2018

1 reference

Monoclonal antibody successes in the clinic

21 January 2018

1 reference

Can the pharmaceutical industry reduce attrition rates?

31 March 2020

1 reference

Improving the efficacy of antibody-based cancer therapies

31 March 2020

1 reference

Engineering antibodies for therapy

31 March 2020

1 reference

Tailor-made antibody therapeutics

31 March 2020

1 reference

Intrabodies as therapeutic agents

31 March 2020

1 reference

Intrabodies: production and promise

31 March 2020

1 reference

31 March 2020

The problem with potency

1 reference

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

31 March 2020

1 reference

Monoclonal antibody therapy of cancer

31 March 2020

1 reference

Engineered antibody fragments and the rise of single domains

31 March 2020

1 reference

Selecting and screening recombinant antibody libraries

31 March 2020

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

Therapeutic antibody expression technology

31 March 2020

1 reference

Generation and production of engineered antibodies

31 March 2020

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

31 March 2020

1 reference

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies

31 March 2020

1 reference

Minimizing the immunogenicity of antibodies for clinical application

31 March 2020

1 reference

Renaissance of cancer therapeutic antibodies

31 March 2020

1 reference

Immunotherapy: past, present and future

31 March 2020

1 reference

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

31 March 2020

1 reference

Production of functional chimaeric mouse/human antibody

31 March 2020

1 reference

Replacing the complementarity-determining regions in a human antibody with those from a mouse

31 March 2020

1 reference

Reshaping human antibodies: grafting an antilysozyme activity

31 March 2020

1 reference

Reshaping human antibodies for therapy

31 March 2020

1 reference

Human antibodies from transgenic animals

31 March 2020

1 reference

A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities

31 March 2020

1 reference

Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs

31 March 2020

1 reference

Antigen-specific human antibodies from mice comprising four distinct genetic modifications

31 March 2020

1 reference

Phage antibodies: filamentous phage displaying antibody variable domains

31 March 2020

1 reference

By-passing immunization. Human antibodies from V-gene libraries displayed on phage

31 March 2020

1 reference

Antibodies from phage antibody libraries

31 March 2020

1 reference

Theoretical studies of clonal selection: Minimal antibody repertoire size and reliability of self-non-self discrimination

31 March 2020

1 reference

Combinatorial protein biochemistry for therapeutics and proteomics

31 March 2020

1 reference

Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library.

31 March 2020

1 reference

The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS

31 March 2020

1 reference

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

31 March 2020

1 reference

An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries

31 March 2020

1 reference

Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries

31 March 2020

1 reference

Minimizing the immunogenicity of protein therapeutics

31 March 2020

1 reference

Immunogenicity of engineered antibodies

31 March 2020

1 reference

Antibody humanization: a case of the 'Emperor's new clothes'?

31 March 2020

1 reference

Antibody pharmacokinetics and pharmacodynamics

31 March 2020

1 reference

Identification of potent human anti-IL-1RI antagonist antibodies

31 March 2020

1 reference

CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range

31 March 2020

1 reference

Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site

31 March 2020

1 reference

Additivity of mutational effects in proteins

31 March 2020

1 reference

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization

31 March 2020

1 reference

Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A.

31 March 2020

1 reference

Redesigning an antibody fragment for faster association with its antigen.

31 March 2020

1 reference

Humanization of an anti-p185HER2 antibody for human cancer therapy

31 March 2020

1 reference

Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency

31 March 2020

1 reference

Integrating cell-level kinetic modeling into the design of engineered protein therapeutics

31 March 2020

1 reference

From the bench to the bedside: ways to improve rituximab efficacy.

31 March 2020

1 reference

Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation

31 March 2020

1 reference

The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation.

31 March 2020

1 reference

The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

31 March 2020

1 reference

In vitro characterization of five humanized OKT3 effector function variant antibodies.

31 March 2020

1 reference

Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection

31 March 2020

1 reference

PHASE I STUDY OF AN ENGINEERED AGLYCOSYLATED HUMANIZED CD3 ANTIBODY IN RENAL TRANSPLANT REJECTION1

31 March 2020

1 reference

Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors

31 March 2020

1 reference

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

31 March 2020

1 reference

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

31 March 2020

1 reference

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

31 March 2020

1 reference

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

31 March 2020

1 reference

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

31 March 2020

1 reference

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

31 March 2020

1 reference

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

31 March 2020

1 reference

Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism

31 March 2020

1 reference

Optimization of humanized IgGs in glycoengineered Pichia pastoris.

31 March 2020

1 reference

Engineered antibody Fc variants with enhanced effector function

31 March 2020

1 reference

Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis

31 March 2020

1 reference

Production and characterization of mice transgenic for the A and B isoforms of human FcgammaRIII.

31 March 2020

1 reference

Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice

31 March 2020

1 reference

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

31 March 2020

1 reference

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

31 March 2020

1 reference

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

31 March 2020

1 reference

Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level

31 March 2020

1 reference

Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,)

31 March 2020

1 reference

Transcytosis and catabolism of antibody

31 March 2020

1 reference

Increasing the serum persistence of an IgG fragment by random mutagenesis.

31 March 2020

1 reference

Engineered human IgG antibodies with longer serum half-lives in primates

31 March 2020

1 reference

Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels

31 March 2020

1 reference

Retargeting serum immunoglobulin with bispecific diabodies

31 March 2020

1 reference

Albumin binding as a general strategy for improving the pharmacokinetics of proteins

31 March 2020

1 reference

Therapeutic antibody fragments with prolonged in vivo half-lives

31 March 2020

1 reference

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

31 March 2020

1 reference

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

31 March 2020

1 reference

PEGylated antibodies and antibody fragments for improved therapy: a review

31 March 2020

1 reference

Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans

31 March 2020

1 reference

In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants

31 March 2020

1 reference

Arming antibodies: prospects and challenges for immunoconjugates

31 March 2020

1 reference

Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli

31 March 2020

1 reference

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

31 March 2020

1 reference

Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies.

31 March 2020

1 reference

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

31 March 2020

1 reference

Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library

31 March 2020

1 reference

Recombinant humanized monoclonal antibody against CD18 (rhuMAb CD18) in traumatic hemorrhagic shock: results of a phase II clinical trial. Traumatic Shock Group

31 March 2020

1 reference

Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer

31 March 2020

1 reference

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

31 March 2020

1 reference

Drug-conjugated monoclonal antibodies for the treatment of cancer

31 March 2020

1 reference

Future directions of liposome- and immunoliposome-based cancer therapeutics

31 March 2020

1 reference

Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells

31 March 2020

1 reference

Selection of tumor-specific internalizing human antibodies from phage libraries

31 March 2020

1 reference

Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway

31 March 2020

1 reference

Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates

31 March 2020

1 reference

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin

31 March 2020

1 reference

Aggregation-resistant domain antibodies selected on phage by heat denaturation

31 March 2020

1 reference

Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C.

31 March 2020

1 reference

Biophysical properties of human antibody variable domains

31 March 2020

1 reference

Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering

31 March 2020

1 reference

Flexibility--the guiding principle for antibody manufacturing

31 March 2020

1 reference

Clinical trials of antibody therapy

31 March 2020

1 reference

Identification and validation of cell surface antigens for antibody targeting in oncology

31 March 2020

1 reference

Localization of the binding site for the human high-affinity Fc receptor on IgG.

31 March 2020

1 reference

The binding site for C1q on IgG

31 March 2020

1 reference

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRI1837

1 reference

14 August 2017

1 reference